GSK plc (GSK)'s Asthma Drug Gets FDA Nod to Treat ‘Smoker's Lung'
The U.S. Food and Drug Administration has approved GSK plc (NYSE:GSK)'s asthma medication, Nucala, for expanded use in treating a form of chronic obstructive pulmonary disease (COPD), often referred to as 'smoker's lung,' the company announced Thursday.
This decision allows Nucala to be used as an add-on therapy for patients with a specific type of COPD. Nucala is a monoclonal antibody that targets interleukin-5, a protein involved in regulating eosinophils—white blood cells that can cause lung inflammation when present in excess.
Though the FDA had originally aimed to make a decision by May 7, the approval came two weeks later, continuing a trend of missed deadlines following recent staffing cuts and restructuring within federal health agencies under Secretary of Health and Human Services Robert F. Kennedy Jr.
The green light was supported by results from a late-stage clinical trial showing that patients taking Nucala along with standard inhaled therapy experienced 21% fewer disease flare-ups over a 104-week period compared to those given a placebo.
In its press release, GSK plc (NYSE:GSK) highlighted that hospitalizations related to COPD are a growing burden on the healthcare system and could soon become the leading cause of medical admissions. Emergency room visits and inpatient treatments already represent a major share of the approximately $7 billion in annual COPD-related healthcare costs in the US.
GSK has surged by nearly 15% in 2025 so far.
While we acknowledge the potential of GSK to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GSK and that has 100x upside potential, check out our report about this cheapest AI stock.
READ MORE: and
Disclosure. None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
19 minutes ago
- Fox News
Fox News beats ABC, NBC, CBS during weekday primetime while CNN has lowest-rated week of year
Fox News Channel beat all broadcast networks in a key metric last week as CNN had its lowest-rated week of the year. Fox News averaged 2.7 million viewers during primetime on weekdays from May 26-30, compared to 2.4 million for NBC, 2.4 million for CBS and 2.3 million for ABC. While Fox News prevailed against the trio of broadcast networks, it also obliterated CNN. Fox News averaged 1.5 million total day viewers from May 26 through June 1, compared to a dismal 308,000 for CNN. During primetime, Fox News averaged 2.3 million viewers while CNN settled for only 374,000. It was much of the same among the advertiser-coveted demographic of adults aged 25-54, as Fox News delivered 175,000 total day demo viewers and 240,000 during primetime, compared to 49,000 total day and 61,000 primetime demo viewers for CNN. CNN finished with its worst week of the year across both primetime and total day as Fox News had its highest cable news share since inauguration week. Along the way, the top 100 cable news telecasts for the week all aired on Fox News. "The Five" averaged 3.7 million total viewers and 409,000 in the critical demo to lead cable news in both categories. "Special Report with Bret Baier," "The Ingraham Angle," "Jesse Watters Primetime," "Hannity," "FOX News @ Night," "Gutfeld!," "Outnumbered," "The Will Cain Show," "America's Newsroom," "America Reports" and Harris Faulkner's "The Faulkner Focus" all had strong weeks, too, to help Fox News crush CNN. Ratings data courtesy of Nielsen Media Research.
CBS News
20 minutes ago
- CBS News
Allina Health doctors, PAs hold first-ever union picket, ask for better work-life balance in new contract
Six hundred Allina doctors, physician assistants and nurse practitioners who work in primary care are asking for a new contract with more work-life balance. They gathered in the pouring rain Tuesday morning for a first-of-its-kind protest. "We are here together as a result of many years of fighting, fighting for primary care and fighting to make things better," workers chanted. While nurses have walked the picket line for years, these picketers are doctors, PA's and nurse practitioners who are admittedly higher compensated. "We all get paid really well, its not about that. It's about having better support for our patients and support in our community and that we want a fair treatment in our contract and protections for everybody," said Dr. Chris Filetti, a pediatrician with Allina Health. WCCO The workers are asking for paid sick leave, instead of having to use vacation time. They're also asking for four hours a week to finish paperwork, instead of doing it in their off time. Additionally, they're asking for more medical assistants and nurses for support. "As a provider I hear story after story about providers who have to cut back from practice because of poor work-life balance," said Filetti. Allina's leaders say they are listening despite the unsettled contract, telling WCCO in a statement: "We continue to negotiate in good faith to reach responsible agreements that maintain competitive pay and benefits for our providers while ensuring that we can sustain our caring mission during these extremely uncertain economic times. It is important to get it right. We remain committed to reaching fair agreements that ensure we can maintain access to the high-quality care people depend on."
Washington Post
23 minutes ago
- Washington Post
Trump promises to hike steel and aluminum tariffs to 50% starting Wednesday. Here's what we know
NEW YORK — U.S. President Donald Trump has promised to hike nearly all of his tariffs on foreign steel and aluminum to a punishing 50% on Wednesday, a move that would hammer businesses from automakers to home builders, and likely push up prices for consumers. Foreign-made steel and aluminum is used in household products like soup cans and paper clips as well as big-ticket items like a stainless-steel refrigerators and cars. Economists warn that the latest tariffs will significantly squeeze the wallets of both companies and shoppers alike.
